{
    "nct_id": "NCT05355805",
    "official_title": "A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa",
    "inclusion_criteria": "General\n\n* Subject has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* 18 years to 75 years of age\n\nType of Subject and Disease Characteristics\n\n* Diagnosis of hidradenitis suppurativa (HS) for ≥ 1 year prior to first dose of study drug.\n* Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III.\n* A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment/randomization.\n* Subject must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS.\n* Must agree to use daily over-the-counter topical antiseptics.\n* Subject must be willing to complete a daily skin pain diary for at least 3 days prior to Day 1 visit.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "Medical Conditions\n\n* Draining fistula count of > 20.\n* Outpatient surgery ≤ 8 weeks prior or inpatient surgery ≤ 12 weeks prior to enrollment/randomization.\n* Other active skin disease or condition that could interfere with study assessments.\n* Chronic pain not associated with HS.\n* Uncontrolled, clinically significant system disease.\n* History of demyelinating disease or neurological symptoms suggestive of demyelinating disease.\n* Malignancy within 5 years.\n* The subject is at risk of self-harm or harm to others.\n* Active infection or history of certain infections.\n* Tuberculosis or fungal infection seen on available chest x-ray taken ≤ 3 months of screening or at screening (Exception: documented evidence of completed treatment and clinically resolved).\n* Known history of human immunodeficiency virus (HIV).\n\nOther protocol defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}